Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521378 · ClinicalTrials.gov registry record
A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus
A clinical trial, sponsored by Diasome Pharmaceuticals.
- Completed
- Registry status
- 6
- Enrollment target
NCT00521378: Completed study, sponsored by Diasome Pharmaceuticals.
NCT00521378 is a clinical trial that has completed, run by Diasome Pharmaceuticals. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00521378 has completed, sponsored by Diasome Pharmaceuticals.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
Study Summary
A study designed to determine the appropriate doses of Oral HDV Insulin at meal times.
Primary Outcome
To determine the dose response of postprandial plasma glucose to escalating doses (increased daily) of Oral HDV-Insulin given as single doses before breakfast, lunch and dinner, in addition to the Diabetes Mellitus (DM) subject's regular oral type 2 therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-09-17 |
| Est. Completion | 2007-10-06 |
What the finished NCT00521378 record still lists
NCT00521378 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00521378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00521378 about?
NCT00521378 is a clinical study titled "A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus". A study designed to determine the appropriate doses of Oral HDV Insulin at meal times.
What is the current status of trial NCT00521378?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2007-09-17. Estimated completion is 2007-10-06.
Who is sponsoring clinical trial NCT00521378?
This trial is sponsored by Diasome Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI